AppliedVR, which provides VR-based therapeutics to patients with chronic pain, raises a $36M Series B, bringing its total funding to $71M
Fred Pennic / HIT Consultant :
Context & Ripple Effects
AppliedVR's $36M Series B lands just days before the FDA authorization of its EaseVRx as a prescription treatment for chronic lower back pain, and roughly eight months after the company's $29M Series A led by F-Prime Capital. The sequencing matters: investors are funding a company that is about to hold a regulatory clearance no other VR pain product has.
The raise also positions AppliedVR against a crowded non-VR digital pain field — Kaia Health has raised successive rounds including a $75M Series C on app-based AI and motion-tracking therapy — while VR healthcare capital flows more broadly into adjacent categories like Osso VR's surgical training platform.
First-order effects
- AppliedVR now has the capital to commercialize EaseVRx at scale immediately following its FDA authorization, converting a research-stage therapeutic into a prescription product with a sales and reimbursement push.
Second-order effects
- App-based rivals like Kaia Health face a competitor whose FDA-cleared status gives it a different payer conversation, pressuring the broader digital chronic-pain market toward clinical validation rather than consumer wellness positioning.
Third-order effects
- If EaseVRx's authorization-plus-funding pattern holds across the sector, VR shifts from a clinician-training tool (the Osso VR model) to a reimbursable prescription category, with FDA clearances becoming the gating asset that determines which startups can raise growth capital.
The trend: Healthcare VR is splitting into two funded tracks — simulation for professionals and FDA-cleared prescription therapeutics for patients — with regulatory clearance emerging as the key fundraising catalyst.